Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | +1.85% |
|
+12.24% | -68.21% |
Jul. 08 | Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201 | MT |
Jul. 08 | Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 | CI |
End-of-day quotes
Sector Biopharmaceuticals
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
58.11M | - | - | - | - | - | |
40.94B | ||||||
33.35B | ||||||
29.53B | ||||||
15.76B | ||||||
13.65B |